CM
Therapeutic Areas
GigaGen Pipeline
| Drug | Indication | Phase |
|---|---|---|
| GIGA-564 | Advanced Solid Tumors | Phase 1 |
| GIGA-2339 | Chronic Hepatitis B Virus (HBV) | Phase 1 |
| Botulinum Neurotoxin Program | Botulism (Biodefense) | Pre-clinical/Development |
Leadership Team at GigaGen
CK
Carter Keller
Chief Executive Officer
AA
Adam Adler, Ph.D.
Chief Scientific Officer
SK
Sheila Keating, Ph.D.
Vice President, Immunology
ES
Erica Stone, Ph.D.
Vice President, Oncology
RM
Rena Mizrahi, Ph.D.
Vice President, Process Development
JF
Jan Fredrik Simons
Senior Director, Technology